{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T07:00:28Z","timestamp":1769929228915,"version":"3.49.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jve.2022.100082","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T23:42:49Z","timestamp":1661298169000},"page":"100082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination strategies to durably suppress HIV-1: Soluble T cell receptors"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5320-4718","authenticated-orcid":false,"given":"Zo\u00eb","family":"Wallace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Dorrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jve.2022.100082_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COH.0000000000000670","article-title":"Long-acting injectable HIV therapies: the next frontier: Republication","volume":"16","author":"Thornhill","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jve.2022.100082_bib2","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the cure of HIV infection by CCR5\u039432\/\u039432 stem cell transplantation","volume":"117","author":"Allers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jve.2022.100082_bib3","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","article-title":"Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report","volume":"7","author":"Gupta","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jve.2022.100082_bib4","first-page":"23","article-title":"HIV-1 remission with CCR5\u039432\u039432 haplo-cord transplant in a U.S. woman:IMPAACT P1107 [CROI ABSTRACT 65]. In special issue: abstracts from the 2022 Conference on Retroviruses and Opportunistic Infections","volume":"30","author":"Hsu","year":"2022","journal-title":"Top Antiv Med"},{"key":"10.1016\/j.jve.2022.100082_bib5","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1056\/NEJMc1412279","article-title":"More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32\/delta32 mutation","volume":"371","author":"Verheyen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jve.2022.100082_bib6","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(20)30234-4","article-title":"Multi-stakeholder consensus on a target product profile for an HIV cure","volume":"8","author":"Lewin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jve.2022.100082_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149414","article-title":"How elite controllers and posttreatment controllers inform our search for an HIV-1 cure","volume":"131","author":"Li","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jve.2022.100082_bib8","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1128\/JVI.00996-12","article-title":"Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys","volume":"86","author":"Stephenson","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.jve.2022.100082_bib9","article-title":"A landscape analysis of HIV cure-related clinical research in 2019","volume":"6","author":"Barr","year":"2020","journal-title":"J Virus Erad"},{"key":"10.1016\/j.jve.2022.100082_bib10","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: international AIDS society global scientific strategy 2021","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jve.2022.100082_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nm0495-330","article-title":"Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression","volume":"1","author":"Koenig","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.jve.2022.100082_bib12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/nm.1779","article-title":"Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor","volume":"14","author":"Varela-Rohena","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jve.2022.100082_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fcimb.2020.00298","article-title":"Virus-specific T cell therapies for HIV: lessons learned from hematopoietic stem cell transplantation","volume":"10","author":"Lee","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jve.2022.100082_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/mt.2014.207","article-title":"Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy","volume":"23","author":"Lam","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jve.2022.100082_bib15","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.ymthe.2018.08.015","article-title":"HIV-specific, ex vivo expanded T cell therapy: feasibility, safety, and efficacy in ART-suppressed HIV-infected individuals","volume":"26","author":"Sung","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jve.2022.100082_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jiv022","article-title":"Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir","volume":"212","author":"Sung","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jve.2022.100082_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003461","article-title":"Extreme genetic fragility of the HIV-1 capsid","volume":"9","author":"Rihn","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jve.2022.100082_bib18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1126\/science.aav5095","article-title":"Structural topology defines protective CD8+ T cell epitopes in the HIV proteome","volume":"364","author":"Gaiha","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jve.2022.100082_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"HOW tcrs bind mhcs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nri3279","article-title":"Why must T cells be cross-reactive?","volume":"12","author":"Sewell","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/protein\/gzg087","article-title":"Stable, soluble T\u2010cell receptor molecules for crystallization and therapeutics","volume":"16","author":"Boulter","year":"2003","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.jve.2022.100082_bib22","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1111\/febs.15780","article-title":"Engineering soluble T\u2010cell receptors for therapy","volume":"288","author":"Robinson","year":"2021","journal-title":"FEBS J"},{"key":"10.1016\/j.jve.2022.100082_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nbt1070","article-title":"Directed evolution of human T-cell receptors with picomolar affinities by phage display","volume":"23","author":"Li","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jve.2022.100082_bib24","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nm.2764","article-title":"Monoclonal TCR-redirected tumor cell killing","volume":"18","author":"Liddy","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jve.2022.100082_bib25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1110\/ps.051936406","article-title":"Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide\u2010MHC without increasing apparent cross\u2010reactivity","volume":"15","author":"Dunn","year":"2006","journal-title":"Protein Sci"},{"key":"10.1016\/j.jve.2022.100082_bib26","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.31503","article-title":"Immune\u2010Mobilizing monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B\u2013infected cells","volume":"72","author":"Fergusson","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jve.2022.100082_bib27","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jve.2022.100082_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/imm.12779","article-title":"Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells","volume":"152","author":"Boudousquie","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.jve.2022.100082_bib29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jve.2022.100082_bib30","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Imc.-202 investigators, overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jve.2022.100082_bib31","series-title":"Proceedings of the American Society of Clinical Oncology Annual Meeting, Chicago, IL USA","article-title":"Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma","author":"Ikeguchi","year":"2022"},{"key":"10.1016\/j.jve.2022.100082_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai9339","article-title":"Listening to each other: infectious disease and cancer immunology","volume":"2","author":"Vance","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3389\/fimmu.2020.00519","article-title":"Editorial: HIV and cancer immunotherapy: similar challenges and converging approaches","volume":"11","author":"Paiardini","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib35","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3389\/fimmu.2019.01842","article-title":"Have cells harboring the HIV reservoir been immunoedited?","volume":"10","author":"Huang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib36","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jve.2022.100082_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib38","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jve.2022.100082_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.jve.2022.100082_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01032-19","article-title":"Revisiting hepatitis B virus: challenges of curative therapies","volume":"93","author":"Hu","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.jve.2022.100082_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterology Hepatology"},{"key":"10.1016\/j.jve.2022.100082_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1436","article-title":"Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B","volume":"4","author":"Lok","year":"2019","journal-title":"Hepatology Commun"},{"key":"10.1016\/j.jve.2022.100082_bib43","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jve.2022.100082_bib44","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","article-title":"Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy","volume":"156","author":"Tan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jve.2022.100082_bib45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterology Hepatology"},{"key":"10.1016\/j.jve.2022.100082_bib46","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","article-title":"Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy","volume":"156","author":"Tan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jve.2022.100082_bib47","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jve.2022.100082_bib48","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.4049\/jimmunol.1203218","article-title":"IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells","volume":"190","author":"Tang","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib50","series-title":"The International Liver Congress","first-page":"S872","article-title":"IMC-I109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study (SAT437)","author":"Bourgeois","year":"2022"},{"key":"10.1016\/j.jve.2022.100082_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.20031799","article-title":"Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells","volume":"199","author":"Wolint","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jve.2022.100082_bib52","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/mt.2016.114","article-title":"Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T-cell receptors","volume":"24","author":"Yang","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jve.2022.100082_bib53","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/infdis\/jiaa777","article-title":"A phase 1\/2 randomized, placebo-controlled trial of romidespin in persons with HIV-1 on suppressive antiretroviral therapy","volume":"224","author":"McMahon","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jve.2022.100082_bib54","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet Hiv"},{"key":"10.1016\/j.jve.2022.100082_bib55","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","article-title":"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial","volume":"395","author":"Fidler","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jve.2022.100082_bib56","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/infdis\/jiab121","article-title":"Gag p24 is a marker of human immunodeficiency virus expression in tissues and correlates with immune response","volume":"224","author":"Wu","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jve.2022.100082_bib57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chom.2016.07.015","article-title":"Single-cell characterization of viral translation-competent reservoirs in HIV-infected individuals","volume":"20","author":"Baxter","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jve.2022.100082_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/3aa92c3d-b6dd-4c6e-8cee-9587ce80a9c9","article-title":"Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can Be detected in vivo","volume":"8","author":"Graf","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jve.2022.100082_bib59","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1074\/jbc.M208268200","article-title":"HLA-E allelic variants correlating differential expression, peptide affinities, crystal structures, and thermal stabilities","volume":"278","author":"Strong","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jve.2022.100082_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0198-8859(96)00241-8","article-title":"Population genetic studies of HLA-E evidence for selection","volume":"52","author":"Grimsley","year":"1997","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib61","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aac9475","article-title":"Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E","volume":"351","author":"Hansen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jve.2022.100082_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg5413","article-title":"Cytomegaloviral determinants of CD8 + T cell programming and RhCMV\/SIV vaccine efficacy","volume":"6","author":"Malouli","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg1703","article-title":"HLA-E\u2013restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities","volume":"6","author":"Yang","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib64","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148979","article-title":"HLA-E\u2013restricted HIV-1\u2013specific CD8+ T cell responses in natural infection","volume":"131","author":"Bansal","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jve.2022.100082_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202149745","article-title":"Structure\u2010guided stabilization of pathogen\u2010derived peptide\u2010HLA\u2010E complexes using non\u2010natural amino acids conserves native TCR recognition","author":"Barber","year":"2022","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jve.2022.100082_bib66","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jve.2022.100082_bib67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jve.2022.100082_bib68","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.3390\/ijms22115632","article-title":"Principles and current clinical landscape of multispecific antibodies against cancer","volume":"22","author":"Elshiaty","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jve.2022.100082_bib69","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152468","article-title":"Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors","volume":"6","author":"Curnock","year":"2021","journal-title":"JCI Insight"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664022000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664022000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:11:51Z","timestamp":1761855111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664022000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2055664022000206"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2022.100082","relation":{},"ISSN":["2055-6640"],"issn-type":[{"value":"2055-6640","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination strategies to durably suppress HIV-1: Soluble T cell receptors","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2022.100082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100082"}}